BVM Capital LLC is a Southeast-based venture capital firm that invests opportunistically. We provide equity capital to early and expansion stage companies with proprietary technology platforms or unique products addressing large markets.

The partners of BVM Capital manage two investment funds: Louisiana Ventures, LP and TVP, LP (Themelios Ventures).

Louisiana Ventures, LP is focused on venture capital and private equity opportunities. Louisiana Ventures, LP is a generalist fund as far as industry preference, and invests opportunistically in high growth equity opportunities. In contrast, TVP, LP is focused on life science opportunities from the Pennington Biomedical Research Center, the world’s leader in diabetes, nutrition and obesity research.

ArcMail Technology has been in business since 2005. Corporate Headquarters are located in Shreveport, LA, with development groups in Washington and Arizona. The Defender line of email archive products has been in production since the summer of 2005 and is currently on its third production release. ArcMail Technology is focused on providing simple, secure, and cost-effective email archive solutions to the small and medium sized business market.

Cadforce, Inc. is a CAD drafting company that provides a "blend-shore" approach to business process outsourcing (BPO) for architects, engineers, and homebuilders throughout the United States . The US market for architectural, engineering, and construction drafting services is estimated at $20 billion. The vast majority of drafting work has been historically performed in-house within these industries. With mounting pressure to reduce production costs within the construction process and a heightened awareness of off-shoring, companies who produce construction documents have been outsourcing drafting and other phases of the architectural and construction documentation process in ever-increasing numbers.

Embera is developing a new drug based on technology developed by Dr. Nick Goeders, Head of the Pharmacology Department at LSUHSC. Embera has developed a combination of two existing, FDA approved drugs. This combination effectively treats addictions with very few side effects. The initial focus will be on cocaine and methamphetamine addiction, but the combination drugs could also be used for alcohol, gambling and other addictions.

With technology licensed from Pennington Biomedical Research Center and the LSU Agriculture Center, Esperance is developing a unique, targeted, anticancer fusion protein that is selectively toxic to cancer cells. Targeting occurs through the designed ligand component that binds singular extracellular receptors on the cancer cell. The potent cytolytic peptide portion of the drug kills the cancer cell. Initial experiments in therapeutic animal models of human cancer showed regression of well-established tumors.

LifeSync® Wireless ECG System is transforming patient ECG monitoring. Through its unique and patented design, the LifeSync® System eliminates lead wires and trunk cables between patients and bedside, 12-lead or transport ECG monitors, allowing freedom of movement throughout the hospital. Using highly-sophisticated Bluetooth® wireless technology*, the LifeSync® System employs two-way radios to collect and transmit patient ECG and respiration data to the hospitals existing ECG monitors. The LifeSync® System can be implemented easily without costly changes to a hospital's infrastructure.

The LifeSync® System is designed to save critical nurse time by eliminating the need to detach and reattach lead wires when transporting patients, and also facilitates patient mobility and ambulation. The system provides the opportunity for enhanced patient comfort and may reduce the risk of cross contamination from the reuse of improperly cleaned lead wires. The LifeSync® System is indicated for continuous monitoring, diagnostic 12-lead ECG and stress testing.

NuPotential produces dedifferentiated cell lines suitable for re-differentiation into multiple lineages and somatic cell nuclear transfer. The company has a radically different method to de-differentiate stem cells in vitro. If proven, this technology could be a platform for a wide array of therapeutic treatments.

Body Evolution develops interactive health media based on peer-reviewed research. We also operate The Body Image Project, a community for body image. Our goal is to provide tools, information and support for people (and lots of them) to enjoy healthier lives.

Imagine improving a person’s health by practicing the skills of a better thought process, so that unproductive behaviors and choices can be neutralized. Imagine applying these new skills to our thoughts, perceptions, fears and beliefs about our own body. We can be aware of behaviors that once were automatic and unnoticed. And while these behaviors are not easily dismantled, they are less daunting. Sustaining this new knowledge and capacity requires commitment, but it is achievable with Body Evolution.

This is what we mean when we invite you to join a movement. A movement towards health, balance and wellness. Thrive with us.

Jenrin Discovery is a privately-held company developing a pipeline of proprietary ‘first-in-class’ small molecule drugs designed to selectively target peripheral tissues. Many marketed or advanced clinical stage non-psychiatric drugs are plagued by a sub-optimal safety profile, due to psychiatric and neurologic side effects. Jenrin applies its technology and medicinal chemistry expertise to structurally modify such drugs so as to prevent penetration across the blood-brain barrier, resulting in negligible or no brain levels of drug. The new peripherally selective (PS) chemical entities retain the pharmacological activity and other essential properties of the original parent drug, but carry little or no risk of neuropsychiatric effects, thus offering a safer alternative to the original parent drugs. The Jenrin strategy of ‘rational drug re-design’ capitalizes on years of medicinal chemistry that were used to optimize the original drug, significantly shortening discovery timelines and lowering development risk.

Development activities have focused on targeted programs, including metabolic disorders, inflammation/pain, and infectious diseases. More than a dozen patent applications have been filed, and more than 1,000 compounds have been synthesized in three programs. Jenrin is seeking a strategic collaboration for its most advanced program targeting diabetes, liver diseases, and obesity.

NuMe Health is developing evidence-based cobiotic™ products designed to alter bacterial populations in the GI tract to prevent and manage serious health conditions. NuMe's initial products and research are focused on prediabetes, diabetes and unhealthy body weight.

NuMe's focus is on cobiotics, which are combinations of food components that we cannot digest but which act to control the Gastrointestinal (GI) microbiota and its environment. NuMe’s cobiotics are designed to encourage healthy bacteria, discourage unhealthy bacteria and create a healthy microbiota environment. Cobiotics are different from probiotics, which attempt to modify the composition of the bacteria in the GI tract by adding relatively small amounts of specific bacteria to the gut. NuMe’s cobiotics contain prebiotics, which provide nutrition that supports the growth of specific beneficial bacteria strains. Cobiotics also contain other components to help provide an optimal GI environment conducive for health.

NuMe's initial cobiotic products are derived from bioactive ingredients in edible plants that promote the growth of specific beneficial bacteria with the potential to positively affect metabolic conditions. NuMe's cobiotic products are evidence-based and are being developed using rigorous scientific methods, including human clinical studies, to assess and validate their health claims.

Calosyn Pharma is a private biopharmaceutical company developing intra-articular therapeutics for osto-arthritis (OA) of the knee. The company's proprietary approach is based upon regulation of ion channel modulators which, among other things, block the synthesis of certain enzymes that cause cartilage destruction. Louisiana Ventures, LP was a founding investor with a diverse group of venture capital funds.

Chow Town is developing an interactive and digital approach to treat and prevent childhood obesity.